首页    期刊浏览 2024年12月11日 星期三
登录注册

文章基本信息

  • 标题:Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination
  • 本地全文:下载
  • 作者:Jia Xin Chua ; Lindy Gillian Durrant ; Yin Ling Chok
  • 期刊名称:iScience
  • 印刷版ISSN:2589-0042
  • 出版年度:2022
  • 卷号:25
  • 期号:11
  • 页码:1-16
  • DOI:10.1016/j.isci.2022.105379
  • 语种:English
  • 出版社:Elsevier
  • 摘要:SummaryThe emergence of SARS-CoV-2 variants raises concerns of reduced COVID-19 vaccine efficacy. We investigated the humoral immunity in uninfected and previously infected ChAdOx1 nCoV-19, BNT162b2 and CoronaVac vaccinees, who have received complete regimes of vaccines by means of a SARS-CoV-2 surrogate virus blocking test. The ChAdOx1 nCoV-19 (p = 0.0013) and BNT162b2 (p = 0.0005) vaccines induced significant higher blocking activity with longer durability against the Spike (S) protein receptor binding domain (RBD) of wild type SARS-CoV-2 than the CoronaVac vaccine in uninfected vaccinees. Prior infection improved protection in the CoronaVac vaccinees. Subsequent investigation on the breadth of SARS-CoV-2 vaccine-induced antibody blocking responses, revealed that all vaccine platforms cross-protected uninfected vaccinees against all variant of concerns, except Omicron. Prior infection protected the ChAdOx1 nCoV-19 and BNT162b2 vaccinees against Omicron but not CoronaVac vaccinees. Our study suggests that vaccines that induce broader sterilizing immunity are essential to fight against fast-emerging variants.Graphical abstractDisplay OmittedHighlights•ChAdOx1 nCoV-19, BNT162b2, and CoronaVac did not protect against Omicron variant•Combination of prior infection and ChAdOx1 nCoV-19 or BNT162b2 cross-protected against Omicron variant•The CoronaVac vaccine had no protective effect against Omicron regardless of infection status•Prolonged target antigen exposure and target diversification are key for next SARS-CoV-2 vaccinesHealth sciences; Immunology; Virology
国家哲学社会科学文献中心版权所有